Renal Impairment Study

Inclusion Criteria: * Body mass index (BMI): 18 to 34 kg/m² (both inclusive) * Men or confirmed postmenopausal women (by medical report verification and defined as exhibiting natural amenorrhea for at least 12 months before screening or as exhibiting natural amenorrhea for at least 6 months before screening with documented serum follicle-stimulating hormone levels \>40 mIU/mL, provided that no prior hormonal treatment has taken place) or women without childbearing potential based on surgical treatment at least 6 weeks before screening such as bilateral tubal ligation, bilateral oophorectomy or hysterectomy (documented by medical report verification). * Subjects with renal impairment: eGFR \<90 mL/min/1.73 m\*2 determined from serum creatinine 2 -10 days prior to dosing. Stable renal disease, i.e. a serum creatinine value determined at least 3 months before the pre-study visit (e.g. during routine diagnostics) should not vary by more than 20% from the serum creatinine value determined at the pre-study visit \- Healthy subjects eGFR ≥90 mL/min/1.73 m\*2 determined from serum creatinine 2 -10 days prior to dosing. Needs to be within the required age and body weight range of Group 1 (which should not vary by more than+- 10 years and +-10 kg to Groups 2-4). Exclusion Criteria: * Clinically relevant findings(e.g. blood pressure, electrocardiogram, ECG; physical examination,laboratory examination) * Relevant impairment in liver function. * Pre-existing diseases (including impairment of liver function) for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal. * Any organ transplant \< 1 year before participation in this study. * Subject under dialysis or planned to start dialysis during participation in the study. * Failure of any other major organ system other than the kidney.